Zydus Lifesciences Limited has informed the Exchange regarding a press release dated September 15, 2023, titled "Zydus receives final approval from the USFDA for Norelgestromin and Ethinyl Estradiol Transdermal System, 150 mcg/35 mcg per day".
Press Release Sep 15 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for a transdermal system used to prevent pregnancy. This approval marks the third hormonal transdermal patch from Zydus' generics portfolio. The product will be manufactured at the company's facility in Ahmedabad.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
In the deck
Earlier from Zydus Lifesciences
- Press Release Sep 13 2023
- Press Release Sep 01 2023
- Press Release Aug 31 2023
- Press Release Aug 25 2023
- Press Release (Revised) Aug 24 2023
Later from Zydus Lifesciences
- Press Release Sep 19 2023
- Press Release Sep 20 2023
- Press Release Sep 29 2023
- Press Release Oct 06 2023
- Press Release Oct 16 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences